The RET proto-oncogene: A molecular therapeutic target in thyroid cancer

Yoshinori Kodama, Naoya Asai, Kumi Kawai, Mayumi Jijiwa, Yoshiki Murakumo, Masatoshi Ichihara, Masahide Takahashi

研究成果: Review article査読

98 被引用数 (Scopus)

抄録

The RET proto-oncogene is responsible for the development of several human inherited and non-inherited diseases. Germline point mutations were identified in multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma. More than 10 rearranged forms of RET, referred to as RET/PTC 1-9, ELKS/RET and RFP/RET, have been cloned from sporadic and radiation-associated papillary thyroid carcinomas. These mutations induced oncogenic activation of RET tyrosine kinase by different mechanisms. To date, various kinds of therapeutic approaches have been developed for the treatment of RET-associated cancers, including tyrosine kinase inhibitors, gene therapy with dominant negative RET mutants, and RNA interference to abrogate oncogenic mutant RET expression. RET and some signaling molecules that function downstream of RET could be potential targets for the development of selective cancer therapeutics.

本文言語English
ページ(範囲)143-148
ページ数6
ジャーナルCancer science
96
3
DOI
出版ステータスPublished - 01-03-2005
外部発表はい

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「The RET proto-oncogene: A molecular therapeutic target in thyroid cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル